Patients with anti-Mi-2, anti-SRP, anti-MDA5, anti-PL-7, anti-EJ, or anti-OJ antibodies did not develop cancer within 3 years of myositis onset (Table 2). This evidence concerns the gene IFIH1 and myositis disease.